Intravenous immunoglobulin is approved for use in allogeneic bone marrow transplant recipients for prevention of graft-versus-host disease (GVHD) and infections, but the minimally effective dose has not been established. In this multicenter, randomized, doubleblind trial, patients undergoing allogeneic marrow transplantation were randomized to receive 100 mg/kg, 250 mg/kg, or 500 mg/kg doses of intravenous immunoglobulin. Each dose was given weekly for 90 days and then monthly until 1 year after transplant. Six hundred and eighteen patients were evaluated. Acute GVHD (grades 2-4) occurred in 39% of the patients (80 of 206) in the 100 mg/kg group, 42% of the patients (88 of 208) in the 250 mg/kg group, and in 35% of the patients (72 of 204) in the 500 mg/kg group (P = 0.344). Among patients with unrelated marrow donors, a higher dose of intravenous immunoglobulin (500 mg/kg) was associated with less acute GVHD (P = 0.07). The incidences of chronic GVHD, infection and interstitial pneumonia were similar for all three doses of intravenous immunoglobulin. The dose of intravenous immunoglobulin also had no effect on the types of infection, relapse of hematological malignancy or survival. Except for more frequent chills (P = 0.007) and headaches (P = 0.015) in patients given the 500 mg/kg or 250 mg/kg dose of immunoglobulin, adverse events were similar for all three doses. These results suggest that 100 mg/kg, 250 mg/kg, and 500 mg/kg doses of intravenous immunoglobulin are associated with similar incidences of GVHD and infections in most allogeneic marrow transplants. These results should be considered when design- 
Intravenous immunoglobulin is frequently administered to allogeneic bone marrow transplant recipients to prevent or modify graft-versus-host disease (GVHD), interstitial pneumonia, and infections. This use is based upon the favorable results of several randomized, controlled trials which prompted a National Institutes of Health (NIH) consensus panel to endorse the efficacy of intravenous immunoglobulin after allogeneic bone marrow transplantation. [1] [2] [3] [4] [5] [6] [7] [8] [9] A meta-analysis of these trials revealed significant reductions in fatal cytomegalovirus (CMV) infections, CMV pneumonia, non-CMV interstitial pneumonia, and transplantrelated mortality among patients receiving prophylactic intravenous immunoglobulin. 10 Three trials also found a reduction of acute GVHD in recipients of intravenous immunoglobulin. 1, 7, 8 Nevertheless, due to concerns about the high cost of large doses (500 mg/kg of body weight) of prophylactic intravenous immunoglobulin, the NIH consensus panel and other investigators emphasized the importance of a clinical trial to determine the minimally effective dose of intravenous immunoglobulin for prevention or modification of GVHD and infections after allogeneic bone marrow transplantation. 9 For this reason, we performed a multicenter, double-blind trial comparing the immunomodulating and antimicrobial efficacy of three different doses of intravenous immunoglobulin in patients undergoing allogeneic bone marrow transplantation.
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Methods
Patients
Patients were eligible for the study if they satisfied the following criteria: (1) undergoing allogeneic bone marrow transplantation for a hematological malignancy or aplastic anemia; (2) 5 years of age or older; (3) receiving a pretransplant preparative regimen of cytotoxic chemotherapy and/or radiation therapy. Patients positive for antibody to human immunodeficiency virus-I (HIV-I), patients with documented viral hepatitis or CMV disease, and patients with renal failure (serum creatinine Ͼ3.0 mg/dl) or respiratory failure requiring mechanical ventilation were excluded. Similarly, any patient with a history of a previous bone marrow or stem cell transplant was excluded. Informed consent approved by the institutional review board at each study center was obtained from each patient or responsible relative.
Study drugs and design
Eligible patients were randomly assigned in a double-blind fashion to receive one of three different doses of intravenous immunoglobulin (100 mg/kg, 250 mg/kg or 500 mg/kg). The 500 mg/kg dose was a dose previously shown to be effective for reducing GVHD and infections after allogeneic bone marrow transplantation. 7 At the time this study was initiated, there was considerable evidence from other studies that intravenous immunoglobulin was efficacious for modification of GVHD and prevention of infectious complications after allogeneic bone marrow transplantation. [1] [2] [3] [4] [5] [6] [7] [8] In addition, the use of intravenous immunoglobulin in bone marrow transplant recipients had been approved by the Federal Drug Administration. 11 Intravenous immunoglobulin was part of the standard care at all the centers participating in this trial. Thus, a control group not receiving intravenous immunoglobulin was not included in the study. Instead, this trial was designed to determine whether a dose-response effect is associated with intravenous immunoglobulin in bone marrow transplant recipients and whether lower, less costly doses of intravenous immunoglobulin (250 mg/kg, 100 mg/kg) are as effective as higher doses of intravenous immunoglobulin (500 mg/kg).
The first dose of intravenous immunoglobulin was given on day −2 before transplant. After transplant, the intravenous immunoglobulin was given every 7 days between day 0 and day 90 and then once monthly between day 90 and day 360. Additional doses of the study intravenous immunoglobulin were allowed during the trial only for treatment of CMV disease or severe thrombocytopenia refractory to platelet transfusions. The study intravenous immunoglobulin was discontinued if one of the following events occurred: (1) serious adverse event definitely related to intravenous immunoglobulin; (2) another intravenous immunoglobulin product was given; or (3) patient's inability to continue in the study due to noncompliance with the protocol or death.
Unselected lots of commercially available Venoglobulin-S (5%) (Alpha Therapeutic Corporation, Los Angeles, CA, USA) were used in the study. The Venoglobulin-S was supplied as a 5% aqueous sterile solution in 50 ml glass vials (50 mg of immunoglobulin/ml). Blinding during the study was maintained by administering each dose at the same volume per patient's weight (10 ml/kg) in three containers containing either intravenous immunoglobulin or 5% dextrose.
Transplantation regimen
Investigators at each study center were allowed to use preparative regimens of chemoradiotherapy and those immunosuppressive agents for GVHD prophylaxis which were considered standard practice at their institution. Each study center also used its own standard agents for prevention and treatment of infections. Cyclosporine, methotrexate, and corticosteroids were the most common drugs given for prevention of GVHD. For prophylaxis of bacterial, fungal, and viral infections, oral quinolones, nystatin, clotrimazole, fluconazole, trimethoprim-sulfamethoxazole, acyclovir, ganciclovir, and CMV-seronegative blood products were given. Treatment of GVHD consisted of increased doses of corticosteroids or cyclosporine, antithymocyte globulin, or a combination of these agents.
Laboratory procedures
Complete blood counts with differential white blood cell count and platelet count, blood urea nitrogen levels, serum creatinine and uric acid determinations, and liver function studies (total bilirubin, aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase) were performed at the time of study entry, within 24 h of the start of each infusion of intravenous immunoglobulin, at the time of readmission to the hospital, and at the time of study completion. Serological tests for hepatitis B surface antigen, hepatitis C antibody (total, IgM and IgG), HIV antibody, and CMV antibody (IgM and IgG) were obtained at the time of enrollment into the study, and at the time of completion of the study. Cultures for bacteria, fungi, and viruses, repeat serological tests for CMV IgM and IgG, chest radiographs, and tissue biopsies were done whenever clinically indicated.
Definitions of GVHD and infections
The criteria for the diagnosis and grading of GVHD have been previously published. 12, 13 Each patient was evaluated for the absence (grades 0 and 1) or presence (grades 2 to 4) of acute GVHD as well as chronic GVHD.
Bacteremia was defined as the isolation of a pathogenic organism from at least one blood culture in association with fever or other signs of infection. Septicemia was diagnosed if a patient with bacteremia also had hypotension. Local infections were defined as either microbiologically documented (positive culture from a site with signs and symptoms of infection) or clinically documented (signs and symptoms of infection at a site with negative cultures). The diagnosis of invasive fungal infection required either the isolation of a fungus from blood culture or the demonstration of fungus in pulmonary secretions, lung tissue, or other organ tissue in association with signs and symptoms of infection. A fungal infection was considered disseminated if fungus was isolated from the blood or found by culture or histology in the tissues of multiple organs. Viral infections were classified as either asymptomatic (positive culture without signs or symptoms of infection) or symptomatic (positive culture with clinical evidence of disease). Interstitial pneumonia was indicated by the presence of interstitial infiltrates on chest radiograph and hypoxemia which were inexplicable by pulmonary edema, septicemia, bacterial infection, or fungal infection. All classifications of infections, GVHD, and adverse events were done in a blinded fashion.
Statistical analysis
Chi-square tests were used to compare differences in the demographic data among the treatment groups. Comparisons among treatment groups for the incidence of acute GVHD were done by the Mantel-Haenszel test.
14 Comparisons of times to specific events were performed by using Kaplan-Meier estimates of survival distributions and the log-rank test. 15 Relative risks for infection and multivariate analyses of risk factors for GVHD were done by the Cox proportional hazard model. 16 Fisher's exact test was used to compare differences in adverse experiences among the treatment groups. Except for nine patients who never received the study intravenous immunoglobulin, all patients were included in the efficacy analysis (intent-to-treat analysis). An independent monitoring group evaluated study data for safety.
The planned sample size for the trial was 526 patients equally divided among the three treatment groups. This sample size was based upon a test of treatment difference for acute GVHD between the 100 mg/kg study group and the 500 mg/kg study group and a test of equivalence for acute GVHD between the 250 mg/kg study group and the 500 mg/kg study group. 14 The sample size estimated for the difference test was based on a two-sided test with a confidence level of 95% and 80% power. The sample size estimated for the equivalence test was based on a two-sided test with a confidence level of 80% and 95% power. The procedure of Munoz and Rosner was used to obtain these estimates. 17 A sample size of 526 patients provided the opportunity to detect at sufficient power a difference in the proportion of patients without GVHD between the 100 mg/kg and 500 mg/kg groups of 0.22 and a difference of 0.16 between the 250 mg/kg and 500 mg/kg groups.
Results
Patient characteristics
From September 1991 to September 1995, a total of 627 patients at 13 bone marrow transplant centers were enrolled in the study. Nine patients never received the study intravenous immunoglobulin and were excluded from analysis. The characteristics of the other 618 patients who received one or more infusions of the study intravenous immunoglobulin are summarized in Table 1 . Two hundred and six patients received the 100 mg/kg dose, 208 patients were Bone Marrow Transplantation given the 250 mg/kg dose, and 204 patients were given a high dose of 500 mg/kg. The three groups of patients were similar in terms of age, underlying disease, disease prognosis, marrow source, pretransplant preparative regimens, the types and doses of agents used for GVHD prophylaxis, and recipient/donor CMV antibody status. A greater number of male patients were in the group given the 100 mg/kg dose (71%) than in the groups receiving the 250 mg/kg dose (56%) or the 500 mg/kg dose (58%) (P = 0.003). There were also more male/male donor/recipient sex matches in the 100 mg/kg group (41% vs 32%, P = 0.05). Other donor/recipient sex matches were similar among the three study groups. Approximately 80% of the patients were 20 years of age or older, while about one-fourth of the patients had unrelated donors. Advanced underlying disease was present in about one-half of the patients in each treatment group. Fifty-two to 56% of the patients were seropositive for CMV antibody before transplant. Table 2 shows the incidences and severity of acute GVHD in the three treatment groups. Acute GVHD developed in 39% of the patients in the 100 mg/kg group, 42% of the patients in the 250 mg/kg group, and in 35% of the patients in the 500 mg/kg group. These differences were not significant (P = 0.344). Kaplan-Meier estimates of the percentage of patients in each group who did not have acute GVHD also showed no significant differences among the three treatment groups ( Figure 1 , P = 0.29). The incidences of grades 3 and 4 GVHD were lowest among patients receiving the 500 mg/kg dose (18%), but these incidences were not significantly different from the incidences of grades 3 and 4 GVHD in the 100 mg/kg group (23%) and the 250 mg/kg group (24%) (P = 0.33).
GVHD
The effects of different doses of intravenous immunoglobulin on the development of acute GVHD were analyzed further in a Cox proportional hazards regression model in order to adjust for other potential confounding factors influencing the incidence of acute GVHD. The factors included in the analysis were dose of intravenous immunoglobulin, age, sex, underlying disease, disease prognosis, marrow source (related, unrelated, HLA-identical, HLAnon-identical), donor-recipient sex match, pretransplant preparative regimen, and method of GVHD prophylaxis (T cell depletion, other regimens). The model demonstrated an increased risk of developing acute GVHD in male patients (risk ratio = 1.461, P = 0.009), patients 20 years of age or older (risk ratio = 1.509, P = 0.027), patients with an unrelated donor (risk ratio = 2.125, P = 0.0001), and patients not receiving a T cell-depleted bone marrow transplant (risk ratio = 3.037, P = 0.015). The dose of intravenous immunoglobulin was not a significant covariate in this model (risk ratio = 0.925, P = 0.331). Similarly, when the Cox proportional hazards regression model was used to determine factors influencing only grades 3 and 4 GVHD, male sex (risk ratio = 2.34, P = 0.0002), an unrelated donor (risk ratio = 3.73, P = 0.0001), and transplantation without T cell depletion (risk ratio = 3.96, P = 0.036) were the significant risk factors. Figure 2 shows the effects of different doses of intra- GVHD = graft-versus-host disease; CMV = cytomegalovirus. *P = 0.003 vs 250 mg/kg and 500 mg/kg groups; **P = 0.05 vs 250 mg/kg and 50 mg/kg groups. a Standard risk: acute leukemia in first remission, chronic myelogenous leukemia in chronic phase, aplastic anemia.
venous immunoglobulin in patients with each of those risk factors for acute GVHD identified in the Cox proportional hazards regression model. These Kaplan-Meier estimates of the percentage of patients without GVHD show that patients with unrelated donors had a lower incidence of GVHD when receiving a higher dose of intravenous immunoglobulin (500 mg/kg). Similarly, in very high-risk marrow transplant patients with all four risk factors associated with acute GVHD (male, 20 years of age or older, unrelated marrow donor, marrow graft without T cell depletion), the 500 mg/kg dose of intravenous immunoglobulin is associated with the lowest incidence of GVHD (Figure 3 ). These differences, however, did not achieve statistical significance (P values of 0.07 and 0.06, respectively). >20 years old Figure 2 Time to development of acute graft-versus-host disease (grades 2-4) among patients with increased risk for acute graft-versus-host disease (male patients, age у20 years old, unrelated donors, or non T cell-depleted marrow graft). Kaplan-Meier product limit estimates of survival distributions to development of acute graft-versus-host disease (GVHD) in the 500 mg/kg, 250 mg/kg and 100 mg/kg groups. 
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Figure 3
Time to development of acute graft-versus-host disease (grades 2-4) among patients with multiple risk factors for acute graft-versus-host disease (male patient, age у20 years old, unrelated donor, and non T celldepleted marrow graft). Kaplan-Meier product limit estimates of survival distributions of time to development of acute graft-versus-host disease (GVHD) in the 500 mg/kg, 250 mg/kg and 100 mg/kg groups.
The incidence of chronic GVHD among the three treatment groups was also compared by both Kaplan-Meier survival distributions and the Cox proportional hazards model. Only the 349 patients free of chronic GVHD before day 100 after transplant and surviving 100 or more days were included in these analyses. The factors included in the proportional hazards model were dose of intravenous immunoglobulin, age, sex, underlying disease, disease prognosis, marrow source, HLA identity, donor-recipient sex match, pretransplant preparative regimen, method of GVHD prophylaxis (T cell depletion, other regimens), and prior grade 2-4 acute GVHD. As shown in Figure 4 , the cumulative incidences of chronic GVHD in the 500 mg/kg group (42%) and 250 mg/kg group (42%) were lower than the 53% incidence in the 100 mg/kg group, but this difference was not statistically significant (P = 0.15). In the Cox proportional hazards model, the dose of intravenous immunoglobulin was not a significant covariate for development of chronic GVHD (risk ratio = 0.85, P = 0.142). An increased risk for chronic GVHD was found in patients 20 years or older (risk ratio = 1.88, P = 0.011) and in patients with an unrelated donor (risk ratio = 1.90, P = 0.002). Prior grade 2-4 acute GVHD was not found to be a significant risk factor (risk ratio = 1.14, P = 0.504). Tables 3 and 4 summarize the types of infection in the three treatment groups from day 0 to day 100 after transplant and between days 100 and 365 after transplant. The overall rates of infection, the types of infection, and the number of deaths from infection were similar for all three doses of intravenous immunoglobulin both before day 100 after transplant and between days 100 and 365 after transplant. Of note, the incidence of CMV disease was 10% or less in each treatment group before day 100 and between 2% and 4% after day 100. There was a very low incidence of interstitial pneumonia (2% or less) associated with all three doses of intravenous immunoglobulin. The rates and types of infections during the early period of neutropenia (Ͻ500 cells/mm 3 ) immediately after transplant were also not significantly different among the three treatment groups.
Infection
Survival, relapse and mortality
All patients were followed for at least 1 year after entering the study or until the time of their death. Overall survival at 1 year after transplant was 52% (107 of 206 patients) in the 100 mg/kg group, 51% (106 of 208 patients) in the 250 mg/kg group, and 52% (106 of 204 patients) in the 500 mg/kg group (P = 0.997). Further analyses of survival rates stratified by age (Ͻ20 years, у20 years), marrow source (related or unrelated), HLA-identity, disease prognosis, pretransplant preparative regimen, and method of GVHD prophylaxis (T cell depletion, other regimens) also revealed no significant differences among the three treatment groups.
Most deaths in each treatment group were caused by relapse of hematological malignancy, GVHD or infection. Among patients with a hematological malignancy, the relapse rate at 1 year after transplant was 10% (19 of 200 patients) in the 100 mg/kg group, 9% (17 of 197 patients) in the 250 mg/kg group, and 9% (18 of 197 patients) in the 500 mg/kg group. Relapsed disease was the cause of death in 19 patients (9%) receiving the 100 mg/kg dose, in 17 patients (8%) receiving the 250 mg/kg dose, and in 14 193 Table 4 Infections from day 100 to day 365 after transplant 100 mg/kg (n = 132) 250 mg/kg (n = 123) 500 mg/kg (n = 120) patients (7%) given the 500 mg/kg dose. Death from GVHD occurred in 18 patients (9%) in the 100 mg/kg group, in 22 patients (11%) in the 250 mg/kg group, and in 11 patients (5%) in the 500 mg/kg group. None of these differences were statistically significant (P = 0.15). The number of deaths from infection was also similar in each treatment group (38 patients or 18% in the 100 mg/kg group, 34 patients or 16% in the 250 mg/kg group, and 32 patients or 16% in the 500 mg/kg group). The most common infectious cause of death was aspergillosis which occurred in 16 (8%) of the 100 mg/kg patients, in 13 (6%) of the 250 mg/kg patients, and in seven (3%) of the 500 mg/kg patients (P = 0.17).
Infusions and adverse events
A total of 8505 infusions were given to the 612 patients. Eighty-eight patients or 14% (41 100 mg/kg patients, 24 250 mg/kg patients, and 23 500 mg/kg patients) received extra infusions of the study immunoglobulin. Indications for these additional infusions were treatment of documented or suspected CMV infection (62 patients), severe thrombocytopenia (24 patients), and investigator's decision (two patients). Adverse events definitely, probably, or possibly related to the intravenous immunoglobulin occurred during 686 of the 8505 infusions (8.1%). Three hundred and seventeen patients (51%) experienced at least one adverse event related to the infusion of intravenous immunoglobulin. Both the number of patients with adverse events and the number of infusions associated with an adverse event were similar for all three doses of intravenous immunoglobulin. Adverse events complicating 1% or more of the infusions were chills, fever, headaches, myalgias, hypertension, hypotension, nausea and vomiting. The respective inciBone Marrow Transplantation dences of these adverse events after infusion of intravenous immunoglobulin in the 100 mg/kg, 250 mg/kg and 500 mg/kg groups were as follows: chills, 2.8%, 3.3% and 2.3%; fever, 2.1%, 3.0% and 2.2%; headaches, 0.9%, 1.4% and 1.9%; myalgias, 1.1%, 2.6% and 2.1%; hypertension, 2.5%, 3.0% and 2.6%; hypotension, 2.3%, 2.1% and 2.0%; nausea, 0.8%, 1.5% and 1.6%; vomiting, 0.8%, 1.2% and 1.1%. Of these common adverse events, only chills (P = 0.007) and headaches (P = 0.015) occurred in a significantly greater number of patients in the 500 mg/kg group (25% and 16%, respectively), or in the 250 mg/kg group (32% and 14%, respectively) compared to the 100 mg/kg group (18% and 7%, respectively). No serious adverse events were attributed to the intravenous immunoglobulin.
There was no significant difference in the incidence of veno-occlusive disease among the three treatment groups. Veno-occlusive disease occurred in 23 patients (11%) in the 100 mg/kg group, 18 patients (9%) in the 250 mg/kg group, and in 24 patients (12%) in the 500 mg/kg group. Hematological, renal, and hepatic laboratory tests also failed to show any significant differences among the three treatment groups. No patients became positive for hepatitis B surface antigen or HIV antibody during the study, while six patients became seropositive for hepatitis C antibody (three with IgM plus IgG, three with IgG only).
Discussion
Despite the previously reported favorable effects of intravenous immunoglobulin in allogeneic marrow transplant recipients, 1-10 the high cost of large doses of immunoglobulin has limited its use at many transplant centers. The present study was designed to determine a minimally effective dose of intravenous immunoglobulin for prevention of GVHD and infections and thereby establish a more costeffective dosing regimen. We found no significant differences in the overall incidence of acute GVHD among the three dosing groups. Acute GVHD developed in 39% of patients in the 100 mg/kg group, 42% in the 250 mg/kg group, and 35% in the 500 mg/kg group. These incidences of acute GVHD are all comparable to the incidences of 34% reported in intravenous immunoglobulin recipients participating in earlier trials at UCLA and Seattle where immunoglobulin at doses of 1000 mg/kg or 500 mg/kg once weekly were associated with less GVHD compared to no treatment. 1, 7 Of note, among patients with unrelated donors, especially if they were male, 20 years of age or older, and did not receive a T cell-depleted graft, the higher dose of intravenous immunoglobulin (500 mg/kg) appeared to be associated with the lowest incidence of acute GVHD (Figures 2 and 3) . A multicenter randomized trial is further evaluating the efficacy of intravenous immunoglobulin in marrow transplant recipients with unrelated donors. 18 The inability of this study to demonstrate any clear relationship between the dose of intravenous immunoglobulin and the incidence of acute GVHD or infections might be interpreted as a lack of benefit of intravenous immunoglobulin in marrow transplants that receive other more updated regimens for prevention of infection and GVHD. Generally, the number of serious infections, especially CMV disease and interstitial pneumonia, were considerably lower in this trial than in earlier studies of prophylactic intravenous immunoglobulin in marrow transplants. [1] [2] [3] [4] 7, 10 Fluoroquinolones, fluconazole, and ganciclovir are effective agents for prophylaxis of infection and were commonly used in this study. [19] [20] [21] [22] [23] Such drugs were either unavailable or not used in previous trials of prophylactic intravenous immunoglobulin. The current availability of these more effective antimicrobial drug regimens for prevention of infection suggests a lesser need to use intravenous immunoglobulin for prophylaxis of infection after marrow transplantation.
On the other hand, acute GVHD continues to be a very common complication after allogeneic bone marrow transplantation despite current combination regimens of immunosuppressive drugs. Furthermore, with expansion of the application of allogeneic marrow transplantation to now include older patients and more patients with HLA non-identical or unrelated donors, the incidence and severity of GVHD has actually increased in certain types of patients. [24] [25] [26] Acute GVHD still develops in approximately 35% to 60% of recipients of HLA-identical, related marrow allografts and in more than half of patients who receive unmanipulated marrow grafts from HLA non-identical or unrelated donors. 27 Thus, the present indications for intravenous immunoglobulin may be stronger for patients at high risk for severe GVHD than for prevention of infections. 28 Additional randomized trials comparing different doses of intravenous immunoglobulin to placebo in patients receiving more effective immunosuppressive drugs for prevention of GVHD could be undertaken to further clarify the role of intravenous immunoglobulin in recipients of allogeneic marrow or stem cell grafts.
One of the potential limitations of this multicenter trial is the diversity of immunosuppressive drug regimens given to prevent GVHD. Approximately 75% of the patients received cyclosporine in combination with methotrexate and/or corticosteroids. However, the use of a single uniform immunosuppressive drug regimen for GVHD prophylaxis in all patients may have provided a greater opportunity to detect any potential differences in the efficacy of the different doses of intravenous immunoglobulin for prevention of GVHD.
Patients with chronic GVHD have persistent defects in both cellular and humoral immune responses. These patients are particularly susceptible to many types of infection, especially infections caused by encapsulated bacteria. 29 Nevertheless, a previous trial evaluating the effects of monthly administration of intravenous immunoglobulin on chronic GVHD and associated infections showed no substantial benefits. 30 In the present study, the overall incidence of chronic GVHD and late infections between days 100 and 360 after transplantation was similar in all three dosing groups. Due to a significant fall in serum IgG levels when intravenous immunoglobulin dosing is changed from weekly to monthly in marrow transplants, 30 a weekly instead of a monthly schedule of intravenous immunoglobulin administration could still be beneficial in those patients with chronic GVHD who also have severe hypogammaglobulinemia.
Two other randomized, unblinded clinical trials evaluating the effects of different doses of intravenous immunoglobulin on complications after allogeneic bone marrow transplantation have been reported recently. In a multicenter trial comparing a 250 mg/kg dose of intravenous immunoglobulin with a 500 mg/kg dose each given once weekly from day 8 before transplant to day 111 after transplant, the incidence of acute GVHD was less in patients receiving the higher dose (44% vs 58%, P = 0.03). 31 Similar rates of infection and survival were observed with both doses. In a single-center trial, adult patients given relateddonor marrow grafts were randomized to receive or not to receive prophylactic intravenous immunoglobulin administered at a loading dose of 500 mg/kg per day from day 6 to day 1 before transplant and then at a lower maintenance dose of 100 mg/kg every 3 days from day 3 to day 90 after transplant. 18 The incidences of acute GVHD, CMV infection, interstitial pneumonia, bacteremia, and mortality were similar in the recipients of intravenous immunoglobulin and the control patients. Interpretation of these results, however, is clouded by the administration of intravenous immunoglobulin to control patients who developed hypogammaglobulinemia (IgG level Ͻ500 mg/dl). Indeed, acute GVHD was less frequent among patients achieving maximum serum IgG levels у3000 mg/dl after the administration of intravenous immunoglobulin. Trough serum IgG levels Ͼ1200 mg/dl were associated with less severe acute GVHD in another study of intravenous immunoglobulin. 32 Serum IgG levels were not routinely followed in our study.
The intravenous immunoglobulin in this study was welltolerated. There were no serious adverse events attributed to the intravenous immunoglobulin. An increase in mortality from veno-occlusive disease of the liver has been reported in allogeneic marrow transplants receiving prophylactic intravenous immunoglobulin at a dose of 500 mg/kg once per week. 33 However, we found no relationship between the dose of intravenous immunoglobulin and the incidence or severity of veno-occlusive disease which occurred in about 10% of all patients in each study group.
In summary, for most allogeneic bone marrow transplant recipients, 100 mg/kg, 250 mg/kg, and 500 mg/kg doses of intravenous immunoglobulin are associated with similar incidences of GVHD, infection, interstitial pneumonia, relapse, and survival. These results should be considered in the development of cost-effective strategies for the use of intravenous immunoglobulin in allogeneic marrow transplants. Since this study was not designed to demonstrate the efficacy of intravenous immunoglobulin compared to treatment without immunoglobulin, another randomized trial of different doses of intravenous immunoglobulin compared to placebo may be indicated as other more effective agents for prevention of GVHD and infection are developed.
